Renal palliative and supportive care in South Africa – a consensus statement by Wearne, Nicola et al.
86
guideline
Renal palliative and supportive care in South Africa –  
a consensus statement 
african Journal of nephrology 
Official publication of the African Association of Nephrology 




























Received 01 April 2020; published 11 May 2020.
Correspondence: Nicola Wearne, nicola.wearne@uct.ac.za, and Rene Krause, rene.krause@uct.ac.za.
©The Author(s) 2020. Published under a Creative Commons Attribution 4.0 International License.
 
AbStRAct
In South Africa, there is a high burden of end-stage kidney disease (ESKD). This is due to the burgeoning epidemics 
of communicable diseases like HIV/AIDS and non-communicable diseases, particularly hypertension and diabetes 
mellitus. One of the most difficult situations encountered by healthcare professionals dealing with patients with 
ESKD in South Africa is the management of a conservative or palliative care pathway for the many patients who 
have no other option. Patients with advanced chronic kidney disease (CKD) have a high burden of physical and 
psychosocial symptoms, poor outcomes and high costs of care.  Many patients are managed in primary healthcare 
settings and either do not have access to palliative care or are not referred appropriately.
Renal supportive and palliative care involves a multidisciplinary approach to managing patients with ESKD, to ensure 
that symptoms are managed optimally and to provide support during advanced disease. It aims to improve quality 
of life for patients and their families and must be provided alongside curative medical care. This support should 
include those unable to gain access to life-saving dialysis and it should also provide care for patients where dialysis 
is not the best option.
The aim of this consensus statement is to assist healthcare providers to improve the management of symptoms and 
biopsychosocial factors of patients with ESKD in a South African context. The document was compiled through 
consensus building among healthcare professionals across South Africa. The professionals represented included 
nephrologists, palliative care physicians, social workers, nurses, paediatricians and hospital managers. We wish to 
acknowledge the contribution of Dr Frank Brennan, a leading expert in renal palliative and supportive care, who 
assisted greatly in the compilation of this document. 
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bAcKGROUND
The incidence of end-stage kidney disease (ESKD) is 
increasing worldwide. In South Africa, the high degree of 
ESKD is due to burgeoning epidemics of communicable 
(such as HIV/AIDS) and non-communicable diseases, parti-
cularly hypertension and diabetes mellitus. However, the 
access to life-saving dialysis and transplantation is severely 
limited in the public health sector.  Palliative and renal sup-
portive care (RSC) aims to relieve the suffering of patients 
and families. Although we are unable to dialyse all patients, 
we can advocate that all patients receive equitable and 
comprehensive renal supportive and palliative care (RSC/
PC). This care must be provided alongside treatment that 
may be curative and must not only be initiated at the very 
end of a patient’s life [1]. In some cases, it may need to 
occur at the time of diagnosis, for example in the case of 
children with multi-organ involvement.
The aim of this document is to improve the care of all 
patients with ESKD whether receiving renal replacement 
therapy (RRT) or not, by integrating nephrology care, 
palliative care and family practice. It aims to align with 
the fundamental principles of Universal Health Coverage 
(UHC) [2] and has the secondary goal of creating awareness 
regarding an alternative conservative management path-
way, where appropriate. It has been written by a multi-
professional team in the hope that it will encourage multi-
disciplinary care and is intended for use by healthcare 
professionals in primary care, internal medicine and 
nephrology in South Africa. 
This document was compiled through consensus building 
among healthcare professionals across South Africa. On 
11 June 2019, 60 participants conducted a workshop in 
Cape Town to define and make recommendations on the 
main concerns and needs of ESKD patients. The pro-
fessionals represented included nephrologists, palliative 
care physicians, social workers, nurses, paediatricians and 
hospital managers from across the country. The workshop 
also hosted Dr Frank Brennan, a leading expert in renal 
palliative and supportive care. He is renowned inter-
nationally, for his work on human rights in health care. 
INItIAtION OF RENAL  
REPLAcEMENt tHERAPY
“Provision of dialysis should benefit the patient, and not just 
prolong life” [3].
In South Africa, there are substantial limitations to accessing 
chronic dialysis [4]. Treatment options are limited in the 
public sector. Many patients, therefore, are on a conserva-
tive pathway, not through choice or medical recom-
mendation, but through circumstance. However, regard-
less of dialysis availability, healthcare professionals should 
address the patient’s personal goals and aims for the future. 
Understanding and communicating prognosis
The ability to prognosticate and communicate prognosis is 
essential [5]. This may be a long process and require 
frequent repeating. There are a few studies that combine 
prognostic factors in clinically useful prediction tools [6,7].
Patient-centred decision making
In ideal circumstances, patient-centred decision making 
should be implemented by a multidisciplinary team [8,9]. It 
should be a family orientated and culturally appropriate 
process where the team and patient agree on a specific 
course of action based on a common understanding of the 
patient’s treatment goals. It should consider the benefits 
and harms of the treatment and the likely outcomes. All 
the possible options should be discussed openly. This 
should include all dialysis modalities, withholding or with-
drawing dialysis and an “opt-out” option for the patient in 
the future after a trial of dialysis. Access to private medical 
insurance should also be discussed.
The timing of the decision-making process is important. 
The Supportive and Palliative Care Indicators Tool (SPICT) 
[10,11] advises that these discussions should be held at 
or when: 
•	 Stage	4	or	5	chronic	kidney	disease	(CKD)	(estimated	
glomerular filtration rate (eGFR) < 30 mL/min/m2) with 
deteriorating health
–   There is also strong evidence for using the Kidney 
Failure Risk Equation (KFRE) to better determine 
progression to ESKD (kidneyfailurerisk.com) [12]
•	 Kidney	 failure	 complicates	other	 life-limiting	 conditions	
or treatment
•	 Ceasing	or	changing	dialysis	modality.
Periodic review of the proposed decision should be 
included in the plan. The timing of these reviews should be 
agreed on at the initial interview. The review should include 
whether dialysis is still benefiting the patient’s personal aims 
or goals and should be revised after any new critical event 
(e.g. after a stroke).
The Renal Physicians Association of America suggests that 
it is reasonable to consider forgoing (not starting or ceasing) 
dialysis for the following groups of patients [13]:
•	 There	is	a	condition	precluding	the	technical	process	of	
dialysis (e.g. an uncooperative patient with advanced 
dementia) or the patient is medically unstable (e.g. 
suffers from profound hypotension).
•	 A	terminal	non-renal	illness	(we	acknowledge	that	some	
may perceive benefit and choose to undergo dialysis).
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•	 Refusal/discontinuation of dialysis in a patient with 
decision-making capacity, who is fully informed and 
making a voluntary choice.
•	 Patients	 who	 no	 longer	 possess	 decision-making	
capacity and who have previously indicated refusal of 
dialysis in an advanced care directive, or those whose 




•	 In	 the	 case	 of	 children,	 it	 may	 also	 be	 appropriate	 to	
withhold renal replacement if the family situation is 
unable to support the child (see paediatric section for 
more details).
•	 Patients	 over	 the	 age	 of	 75	 years,	 who	 have	 two	 or	
more of the following poor prognostic criteria:
–   Depend on others for care due to increasing 
physical and/or emotional and/or mental health 
problems
–  Significant weight loss (> 10%).
–   High comorbidity score, e.g. modified Charlson 
Comorbidity Index score of 8 or greater [14] (see 
Addendum 1).
•	 	Significantly	impaired	functional	status,	such	as	Karnofsky	
score < 40 with limited reversibility [15] (see Adden-
dum 2). 
•	 The	patient	asks	for	palliative	care,	or	chooses	to	reduce,	
stop or have no treatment.
SYMPtOM MANAGEMENt IN ESKD
Patients with advanced CKD experience multiple symp-
toms that contribute to their disease burden [16]. 
These guidelines are compiled to assist healthcare pro-
viders in managing patients with symptoms associated with 
advanced CKD. 
Validated scoring tools
The routine screening of physical and emotional symptoms 
is recommended at each consultation using a validated 
tool. Recommended tools include: 
1)   Integrated Palliative Care Renal Outcome Scale–Renal 
(IPOS–Renal) [17-19] (see Addendum 3).
2)   ESAS-r (Edmonton Symptom Assessment System-
revised: Renal) [20] (see Addendum 4).
3)  Brief Pain Inventory [21] (see addendum 4). 
The causes of a patient’s symptoms other than the kidney 
disease should always be considered. Table 1 describes 
the management of common symptoms using a stepwise 
approach, utilizing medicines that are predominantly on 
the Essential Medicines List (EML). Adjusting the dose for 
renal function is important. The golden rule is start low and 
go slow, with frequent reassessment. 
cOMMUNIcAtION AND ADVANcE  
cARE PLANNING
Essential communication with patients and 
families with ESKD
Compassionate and effective communication is key to 
developing a working and trustful relationship between 
patients, families and healthcare professionals. It requires 
knowledge about what, with whom and when difficult 
conversations should be had. A positive, non-judgmental 
attitude should be maintained. These skills can be taught 
and should be practised. Protocols such as SPIKES (breaking 
bad news) and the “Serious Illness Conversations” are 
examples of evidenced-based approaches to communica-
tion [36,37,39]. All breaking bad news conversations, 
especially around withholding or withdrawing dialysis, 
should be managed by a senior doctor on the team. 
One of the most difficult challenges is the discussion with a 
patient in the public sector who cannot be offered dialysis. 
It is essential that everybody gives the same message when 
communicating with patients and families in order not to 
create false hope or distrust. All difficult conversations 
should be clearly documented in the patient notes. Such 
conversations should always be followed by reflection and, 
if necessary, debriefing. The moral distress of doctors 
involved in withdrawing or withholding dialysis requires 
collegial support from managers and other healthcare 
providers.
There are many barriers to having essential conversations 
with patients and families. Patient and/or family may 
misunderstand the diagnosis and prognosis, there may be 
cultural differences, clinician attitudes and beliefs around 
palliative care, lack of training and shortage of time available 
for difficult conversations. These conversations should aim 
to manage conflict, to acknowledge and address all emo-
tions, to improve prognostic awareness and align care with 
expectations of patients and families. 
The following are recommended essential conversations 
that should take place between healthcare professionals, 
patients and families: 
a.   Breaking Bad News [38] – must offer a hopeful, 
achievable alternative with a carefully considered 
palliative care plan
b.  Serious Illness Conversation [39].
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table 1.  Management of common symptoms of advanced CKd [16,22].
symptom Prevalence likely causes Management















Avoid alcohol, greasy, spicy, sweet and 
bitter-tasting food and drinks
Postprandial upright position
Complementary therapies (ginger, 
relaxation, acupuncture, etc.)
•		Metoclopramide	(low	dose)	5–10	mg	
tds (oral, SC or IM) half-an-hour before 
meals. Start with 5 mg tds and titrate to 
maximal dose of 10 mg tds [23]
•		Haloperidol	0.5–1.5	mg/24	h	CSCI/PO/
SC initiation dose. Max dose 5 mg/24 h.  
For occasional use dose unchanged, for 
regular use half the dose [23]
recommended but not on the edl 
•		*Ondansetron 4–8 mg tds (oral or SC/
IV) (caution: very constipating)






Bulking agents like fibre are not 
recommended for patients using 
constipating medication or with decreased 










25–40% It is normal to feel 
sad when diagnosed 
with a life-threatening 
illness. However, 
when low mood is 
constant, depression 
needs to be 
excluded.
Manage distressing symptoms: psycho-
social and spiritual factors that can 
contribute to anxiety and low mood.
Patient and family education and support.
Support groups or encourage support 
from family, peer groups, religious leaders 
and friends.
In the case of children, attempt to get the 
patient to school even if for short periods. 
Exercise improves mood and anxiety in 
CKD patients. 
Involvement of occupational therapist, 






assist with sleep disturbance (titrate 
according to response up to 25 mg)
•		Lorazepam	0.5–1.0	mg	sublingual	or	
















Bath in lukewarm water and use 
fragrance-free soap
Pat dry
Moisturize with aqueous emollients
•		Antihistamines have a very limited role. 
•		*Pregabalin 25–75 mg (initiate at  
25 mg nocte and titrate up slowly. ESKD 
on a conservative pathway, 25 mg on 
alternate nights)
•		UV-B	light	therapy	may	be	beneficial	in	
patients with refractory symptoms (may 
only be offered in tertiary centres)
•		Patients	on	dialysis:	dialysis	adequacy	and	
calcium and phosphate balance should 
be addressed
recommended but not on the edl
•	Capsaicin	cream	0.025%	
•		*Gabapentin 100–200 mg nocte (initiate 
100 mg nocte alternate days and titrate 
up slowly. If the patient is on dialysis this 
should be given after dialysis) 
renal palliative and supportive care in south africa
Advance Healthcare Planning
Advance Healthcare Planning includes discussions with 
individuals about their preferences and wishes. They are 
best held when patients are relatively well, able to 
communicate effectively and have the mental capacity to 
make independent decisions.  They should address values, 
goals and outcomes that are important to patients and 
families. The conversation should be ongoing and not a 
single event with the possibility of review if circumstances 
change. The plan will assist the healthcare team to make 
treatment recommendations that are aligned with specified 
values. This becomes increasingly important when the 
patient is no longer able to make or verbalise decisions 
independently. Research shows that patients expect 
91
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table 1 (continued).  Management of common symptoms of advanced CKd [16,22].
symptom Prevalence likely causes Management
non-pharmacological Pharmacological  (stepwise approach)
Pain [18,30-32]
No studies on 
long-term use  









acupuncture or heat therapy 
•		Behavioural	therapy:	cognitive	
behavioural therapy, relaxation therapy
•		If	there	is	an	identified	pain	syndrome	
(e.g. OA, diabetic peripheral neuropathy, 
cancer, gout) treat according to 
guidelines for that syndrome for the 





50 mg bd or oxycodone 5–20 mg tds) 
titrate up slowly (*oxycodone is not on 
the EDL)
•		Morphine:	generally,	not	recommended,	
as metabolites are renally excreted and, 
in normal doses, will cause toxicity. If 
used, should be used with significant 
caution. Advised for moderate to 
severe pain syndromes. Start with 1–2.5 
mg PO/SC prn and titrate to affect. If 
pain is stable, consider switching to a 
transdermal fentanyl patch [23]
recommended but not on the edl
•		*Transcutaneous patches: (only use when 
pain is stable)
   – fentanyl 12.5, 25 µg 
   – buprenorphine 5 µg 
neuropathic 
pain
Same as pain above •		*Pregabalin 25–75 mg (initiate at  
25 mg nocte and titrate up slowly. ESKD 
on a conservative pathway, 25 mg on 
alternate nights)
•		Amitriptyline	10	mg	nocte	may	also	be	
effective, assisting with both neuropathic 
pain and sleep disturbance (may titrate 
according to response up to 25 mg) 
•		Add	opioids	(as	in	section	above):		
stepwise process if moderate to severe 
pain in titrated doses.
recommended but not on the edl
•		*Gabapentin 100–200 mg nocte (initiate 
100 mg nocte alternate days and titrate 
up slowly. If the patient is on dialysis, this 




















e.g. relaxation therapy, meditation
•		Optimize	sleep	hygiene	(no	stimulants,	






pain and obstructive sleep apnoea
•	If	pain	present	treat	as	above
•		Amitriptyline	10	mg	nocte	may	also	be	
effective, assisting with both neuropathic 
pain and sleep disturbance (may titrate 
according to response up to 25 mg)
drugs recommended but not on edl
•		*EPO if available (see KDIGO guidelines) 
[34] 
•		*Melatonin (if available) 2 mg po 1–2 h 
prior to sleep
92
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table 1 (continued).  Management of common symptoms of advanced CKd [16,22].
symptom Prevalence likely causes Management
non-pharmacological Pharmacological  (stepwise approach)














10–20% Anaemia and iron 














reserve bedroom for sleep)
•		Complementary	activities	(acupuncture,	
massage)
•		*Pregabalin: 25–50 mg may also be used 
in divided or single night-time dose. 
Higher doses may result in side effects 
in patients with stage 5 CKD. Start at 25 
mg and titrate to effect
recommended but not on edl
•		*Gabapentin 50–300 mg in the evening. 





















furosemide titrated up to 250 mg daily
•		Hydrochlorothiazide	may	be	added	in	
doses of 12.5–25 mg daily
dyspnoea not due to fluid overload
•		Morphine:	1–2	mg	prn,	with	or	without	
haloperidol 0.5 mg 8-hourly as an anti-
emetic
•		Lorazepam	1	mg	sublingually	or	orally	
may be added to assist with the control 
of anxiety related to dyspnea
Abbreviations: mg, milligram; tds, three times daily; SC, subcutaneous; IM, intramuscular ; PR, per rectum; h, hour; CBT, cognitive behavioural therapy; CSCI, continuous 
subcutaneous infusion; EDL, Essential Drugs List; eGFR, estimated glomerular filtration rate; po, per os; od, once daily; qid, six-hourly; IV, intravenous; mL, millilitres; UV-B, 
ultraviolet; EPO, erythropoietin; prn, as required.
*Drugs not available on the EDL or requiring initiation at a tertiary hospital.
clinicians to initiate these conversations, and when skilfully 
done it does not increase anxiety or hopelessness.
examples of how to start the conversation:
•	 routine visit: “It seems you are doing well but I like talking 
to all my patients about their preferences for care in case 
they get very sick.”
•	 episode of acute illness: “To make sure we are working 
together while you are sick, I would like to talk about your 
goals of care.”
“I would like to talk to you about your current symptoms 
and how you would like us to manage it.“
•	 Follow-up visit after an episode of acute illness: “What 
would be your goals of care if this happens again?”
topics to discuss:
•	 Substitute	decision	makers	or	patient	advocates:	“Who	






•	 What	 have	 you	 learned	 from	 previous	 experiences	




with decision makers and all decision makers are 
comfortable with the decisions.
•	 All	 communication	 should	 be	 clearly	 documented	 and	
included in the patient notes [38].
See Addendum 4 for the link to the Hospice Palliative Care 
Association of South Africa (HPCA) Advance Health Care 
Planning document. 
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PRESERVING RENAL FUNctION AND 
MANAGING cOMPLIcAtIONS OF  
RENAL FAILURE
Screening for CKD must be conducted in high risk 
individuals at each interaction with the healthcare system. 







The guidelines that follow are specifically aimed at CKD 
stages 4 and 5 (Figure 1). Table 2 describes management 
strategies to preserve residual renal function and manage 
complications of CKD.
END-OF-LIFE cARE IN END-StAGE 
KIDNEY DISEASE
Ethical and compassionate care is the main goal when 
managing a patient at the end of life. This period can be 
defined as a “period of irreversible functional decline prior to 
death” [49]. Care plans need to be adjusted to allow 
patients to have a “good death”, where distressing symp-
toms and suffering are treated competently and com-
passionately. The ethical framework that underpins end- 
of-life care [49] includes: 







•	 Families	 should	 be	 actively	 supported	 during	 this	 time	
and during their bereavement.
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Figure 1.  Classification of chronic kidney disease by gFr and degree of albuminuria. Patients at low or moderate risk for 
disease progression (green/yellow) should be followed up at least yearly, those at high risk (orange) twice-yearly, and those at 
very high risk (red) should be seen three or more times per year, as required. reproduced with permission from KdigO [40,41].
abbreviations: CKd, chronic kidney disease; gFr, glomerular filtration rate; KdigO, Kidney disease: improving global Outcomes. 













































G1 Normal or high ≥ 90
G2 Mildly decreased 60–89
G3a Mildly to moderately decreased 45–59
G3b
Moderately to  
severely decreased
30–44
G4 Severely decreased 15–29
G5 Kidney failure < 15
94
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table 2.  strategies to preserve residual renal function and manage complications of stages 4 and 5 CKd [22].
aim/target of treatment non-pharmacological Pharmacological 
General measure: 
lifestyle
Aim: to balance preservation 


















ARBs if dehydrated 
BP (recommend 
review of the 
sa hypertension 
guideline) [42]
Aim: to optimise QOL, preserve 
physical and cognitive function and 
minimise the risk of orthostatic 
hypotension [22]




(e.g. relaxation techniques and music) 
Furosemide titrated to effect (titrate to 
250 mg bd)
Avoid K+ sparing agents if potassium 
is >5.6 mmol/L, i.e. (ACEi/ARB/
spironolactone) unless regular 3-monthly 
blood tests can be done








unsalted herbs, garlic, ginger, chillies
•	Avoid	processed	and	canned	foods
diuretics (if not anuric):
•		Loop	diuretics	are	most	effective:	
furosemide titrated up to 250 mg daily
•		If	short	of	breath,	see	Table	1
acidosis Prevent symptoms associated with 




>23 mmol/L and within upper limit  
of normal range [43,44] (level of 
evidence 2B)
•		Starting	dose:	Citrosoda	4	g,	sodium	
bicarbonate (1.5–2 g) or baking soda 
½ teaspoon dissolved in 125 mL  
water = 26.8 mEq bicarbonate






see KdigO  
guideline [34]




The overall aim is to treat symptomatic 
anaemia
•		Oral	supplementation	(e.g.	iron	




IV iron can be given as a max dose of 
200 mg IV stat or total dose infusions 
of 1000–2000 mg
•		Targets	for	CKD	patients	include	
transferrin saturation 20–30%, and 
ferritin >300 ng/mL
•		Erythropoietin	(EPO)	supplementation:	
only if the patient is symptomatic with 
anaemia and only if available to the 
patient 
•		Transfusions	of	packed	red	cells	may	be	
necessary if the patient is symptomatic, 
particularly if EPO is not available
Calcium and 
phosphate metabolism: 
see KdigO  
guideline [45]
Aim: should not be to focus on 
normalising biochemistry but 
rather on emphasising adequate 
nutrition
Emphasize adequate nutrition (avoid 
malnutrition)
Avoid high phosphate containing food 
(dairy, nuts, legumes, etc.)
•	Liberalize	the	diet
•		Continue	vitamin	D	supplementation,	
and phosphate binder if patient is 




mg total calcium per day – take with 
meals (e.g. Titralac/chewable B-Cal/
Glycal II tds with food)
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essential care steps:
•	 All	 members	 of	 the	 care	 team	 should	 communicate	
effectively with one another so that the advanced care 
plan, should there be one, is respected and instituted.
•	 All	 members	 of	 the	 care	 team	 should	 be	 adept	 at	
communicating compassionately with the patient and 
the family in order to break bad news and initiate 
discussions around withdrawing or withholding artificial 
nutrition, inappropriate hydration and medically inappro-
priate investigations or interventions.
•	 The	patient’s	 decision	 regarding	place	of	death	 should	
be respected as far as possible.
•	 Medication	management:
–   Rationalise medications: stop those not contributing 
to improvement in quality of life.
–   Prescribe medication to treat symptoms and anti-
cipated problems.
–   Use an effective route, especially if the patient 





–   Families need to be compassionately informed 
about the prognosis and should be provided with 
information around the expected symptoms and 
management. Healthcare providers should be led 
by the families around the type and amount of 
information provided.
–   Children need to be appropriately addressed with 
suitable referrals being made where necessary.
–   Prepare the patient’s family and carers regarding 
bereavement, building resilience and practical 
aspects of handling the deceased’s body and 
dealing with undertakers – all of which should be 
respectful of the patient’s cultural and religious 
preferences.
•	 Spiritual	 care	 should	 be	 offered	 and	 provided	 to	 all	
patients and families.
•	 Support	 for	healthcare	professionals	 involved	 in	 caring	
for the deceased should be provided and include 
debriefing and building resilience.
•	 Auditing	 and	 reflection	 of	 this	 process	 would	 allow	
improvement in the managing of the dying patient 
with ESKD.
SERVIcE PROVISION AND 
cOLLAbORAtIVE cARE
the ideal model for palliative care in  
cKD [16]
Healthcare utilisation in advanced CKD is high [50]. There 
are limited data on the cost-effectiveness of renal supportive 
care frameworks [51]; however, there is more solid 
evidence for other illness, such as cancer [50]. Supportive 
care may reduce hospitalisations, intensive care admissions 
and emergency room visits and result in fewer deaths in 
acute care facilities [50]. Cost benefit also needs to be 
analysed in terms of personal cost. The burden experienced 
by families include physical, emotional, social, and economic 
dimensions. An integrated service from the start of dialysis 
until death and into bereavement to support families has 
been reported as an option to improve clinical care [52].
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table 2 (continued).  strategies to preserve residual renal function and manage complications of stages 4 and 5 CKd [22].
aim/target of treatment non-pharmacological Pharmacological 
diabetes
see south african 
diabetes guidelines [46]
Aim: simplify medication regimens. 
As CKD progresses, the need for 
medications decreases.






progresses, the need for insulin 
decreases and requires patient 
education and monitoring of blood 
sugar levels
lipid No evidence that statins 
provide benefit in context of 
significant frailty or decreased life 
expectancy [47,48]
•	Emphasize	adequate	nutrition •	Stop	statin





renal failure, e.g. metformin and digoxin
•	Adjust	drug	dose	for	renal	function
Abbreviations: HIV, human immunodeficiency virus; ART, antiretroviral therapy; TDF, tenofovir ; QOL, quality of life; NSAID, non-steroidal anti-inflammatory drug; ACEi, 
angiotensin converting enzyme inhibitor ; ARB, angiotensin receptor blocker; bd, twice daily; Hb, haemoglobin; BP, blood pressure.
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the current challenges to providing an integrated rsC/
PC service include:
•	 Disparity	of	access	to	renal	replacement	therapy	(RRT)	





•	 Under-utilisation	of	 home-based	 care	 and	 community-
orientated primary care workers
•	 Unclear	 trajectory/prognosis	 of	 many	 patients	 with	
advanced CKD.
critical elements of creating a renal 
supportive clinic
There are numerous aspects that need to be considered 
when creating an RSC/PC clinic. First, there needs to be 
strong collaboration between multiple disciplines, including 
the nephrologist, primary caregiver (GP), palliative care 
physician, social worker and nursing staff. Second, there 
needs to be awareness of all available palliative care 
options and support structures in both the private, public 
and NGO sectors. Third, resources need to be appro-
priately allocated at primary, secondary and tertiary care 
levels. This will require discussions with government, 
hospital management and medical insurance companies. 
In a resource-limited setting, upskilling staff at all healthcare 
levels through education and exposure is essential. A multi-
disciplinary RSC/PC clinic would serve as a platform to 
expand training, create awareness and upskill across the 
care continuum. Establishment of this clinic could be done 
at a tertiary centre, with primary healthcare physicians 
rotating through this service and nephrologists supporting 
community health centres with outreach. Once a care plan 
is formulated, it should be continued at primary level care 
and community-based services (home-based carers) should 
be involved.
Improved communication is essential between all health-
care levels. This can be achieved with a simple booklet for 
patients (a roadmap), which would detail the advanced 
care plan (ACP) and current treatments. Electronic health 
platforms are also becoming increasingly common. Tech-
nology needs to be used by health professionals to link 
peripheral teams to the expertise of the multidisciplinary 
team. A call-in/Skype system could be used during the 
multidisciplinary clinic to support primary carers with advice 
on clinical management and symptoms. Web-based infor-
mation is a cost-effective tool to assist families in providing 
care. It could offer information to connect family and 
relatives to resources and support structures in both the 
private, public and NGO sectors. A study showed that 
families caring for a dying patient required the following 
information: knowledge of the condition, information on 
medication, patient hygiene and nutritional care, contacts 
for emergency support and support options for the 
carer [53].
In a cost-constrained environment, the use of the whole 
team needs to be optimised, which in the South African 
setting includes home-based care, community nurses and 
may involve trained volunteers as a possible innovative 
solution. The literature also states that the presence and 
availability of nurses was found to be crucial for volunteers, 
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table 3.  Possible recommendations for creating a renal supportive care clinic.
recommendations logistics advantages disadvantages
Hospital passport •		Information	booklet	kept	by	the	
patient providing hospital staff with 
vital information regarding:
   –  Diagnosis
   –  Advanced care directive
   –  Medication
   –  End-of-life plan
•		Improved	integration	of	care	









at a primary care 
centre
•		Staff:	social	worker,	nursing	staff	and	
primary healthcare doctor; access to 
nephrologist, dietician and palliative 
care trained physician
•		Focused	on	counselling	and	linking	













through to primary setting
Multidisciplinary renal 
supportive clinic at a 
tertiary centre
•		Focused,	structured	visits	prior	to	
transfer to primary care
•		Staff:	nephrologist,	social	worker,	
nursing staff, primary healthcare 




co-ordinate care between primary 
and tertiary care facilities
•		The	focus	should	be	on	counselling,	




healthcare document retained by the 
patient)
•		Provides	support	to	patients	not	
eligible for renal replacement (formal 






   –   Upskill nephrologists in palliative 
care
   –   Upskill primary healthcare 
physicians in preservation of 







access to medication •		Discussion	with	Pharmacology	and	
Therapeutics Committees (PTC) and 
provincial health management
•		Advocacy	to	have	access	to	
restricted medications for ESKD 
symptom management at all levels of 
care (in public sector)
•		Advocacy	for	authorisation	of	






different languages in a culturally 
sensitive format
•		Highlighting	information	and	












nurse practitioners to manage 










renal palliative and supportive care in south africa
both for support and to achieve integration through 
collaboration [54]. Upskilling community-based nurse prac-
titioners to train, monitor and supervise lay counsellors and 
volunteers (or home-based carers) remains a viable option 
to care within our communities. Table 3 describes possible 
solutions for creating a renal supportive care clinic.
SPEcIAL cONSIDERAtIONS IN 
PAEDIAtRIc PAtIENtS
Decision making around renal replacement 
therapy
The overriding ethical principle in paediatrics is the “best 
interests of the child” standard, where the burden and 
benefit of an intervention such as RRT are considered [55]. 
The preferred mode of dialysis in children is peritoneal 
dialysis as it facilitates normal school, family and play 
activities [56]. However, each family needs to be assessed 
in their context to decide which pathway of care would be 
in their best interest. This assessment is influenced by 
community infrastructure, family stability, financial resources, 
existing healthcare systems, compliance record, and quality 
of life. Methods of communicating information to children 
at different neurodevelopmental stages and with varying 
capacity need to be considered.
Management options for children with  
ESKD [57]
•	 Pre-emptive	kidney	transplantation	is	the	ideal	treatment	





choice of treatment modality
The choice of treatment modality should be decided upon 
by considering the following factors [57]:
•	 Contraindications	to	a	specific	form	of	dialysis
•	 Caregiver/parent	 and	patient	preference	 (where	 appli-
cable)
•	 Quality	 of	 life	 factors	 of	 patient	 and	 family	 including	
siblings
•	 Treating	 practitioner’s	 advice	 (including	 nursing	 and	
allied health).
Suitability for renal replacement therapy
In lower- and middle-income countries, psychosocial and 
economic factors may play a larger role in the selection 
criteria, especially where families are responsible for the 
financial payment of treatments [58,59]. If a child is not a 
suitable RRT candidate, one needs to question the value 
of continuing dialysis, as it has the potential to prolong 
dying rather than to improving quality of life [55]. The 
burden of dialysis can outweigh the benefits of providing 
treatment and violates the medical maxim of maleficence 
(do no harm). It is appropriate to withdraw or not to 
initiate dialysis in children if the dialysis is harmful, is of no 
benefit or prolongs the dying process [60]. Harm may 
include psychosocial factors such as institutionalisation, 
family fragmentation, financial destitution or isolation from 
culture and community. 
RSC/PC should then be considered during a shared 
decision-making process. However, it is essential that the 
nuclear family and, if possible, the extended family be 
involved in the decision-making process. Neonates and 
infants with ESKD and comorbid conditions have a poorer 
prognosis and are a challenge from an access and surgical 
aspect. RSC/PC may often be the care pathway for many 
patients in this group. Psychosocial support, including 
anticipatory bereavement, peri-natal advance care planning 
and memory work, should be integrated into their 
management plan from the time of diagnosis [61]. Shared 
decision making is encouraged in conjunction with a multi-
disciplinary team and, potentially, an appointed neutral 
parent or family member as in the SONG-Kids initiative 
(www.songinitiative.org) [55].
Renal transplantation
The goal to provide a renal transplant is in line with the 
United Nations Convention on the Rights of the Child, 
that states that children have the right to live and enjoy 
the highest attainable standard of health, and govern- 
ments should ensure that children survive and develop 
healthily [62]. Care of a renal graft requires strictly defined 
boundaries and dependence on life-long compliance to 
medication, medical surveillance and significant life-style 
adaptations [63]. Each transplant centre should have its 
own pathway of care to ensure a successful transplant. 
Centre-specific guidelines should advocate that patients 
and their families be fully informed about diagnosis, prog-
nosis and treatment options. 
the role of paediatric palliative care in 
paediatric renal supportive care
Paediatric palliative care (PPC) provides an active approach 
to reduce disease burden and improve quality of life for 
both the child and family, through formulation of manage-
ment plans by a multidisciplinary team. These plans address 
distressing symptoms in different domains of well-being: 
physical, spiritual, social, cultural and psychological. Offering 
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early PPC as an integral part of paediatric renal supportive 
care (RSC) should be done routinely [64,65].
Active palliative care interventions include symptom 
management, medical and prognostic counselling, facilitation 
of family meetings and discussion of ethics, advance care 
planning as well as difficult discussions about end-of-life 
care. Resuscitation status, terminal care and bereavement 
support should also be addressed. Families that are 
receiving RSC often request pain management, clarification 
of treatment goals and relief from emotional and social 
distress as well as management of the patient’s siblings [66].
RSC requires clinicians, allied health and psychosocial team 
members with generalist palliative care training to achieve 
comprehensive care [64]. PPC specialists are rare in 
lower- and lower-middle-income countries (LLMIC), so it is 
imperative that the generalist paediatrician (or general 
practitioner) adopt a palliative care approach so that it is 
incorporated into the multidisciplinary team [67]. The 
demand for generalist health professional knowledge and 
skills in PPC is growing in response to heightened recog-
nition of the benefits of a palliative approach across the 
neonatal, paediatric and adolescent lifespan. Unfortunately, 
there is still no government paediatric palliative care policy 
implementation in South Africa. Paediatric palliative care in 
South Africa is currently provided by the NGO sector. 
Ongoing advocacy from the nephrology community to 
develop PPC education projects would elevate the quality 






Delivery of PPC education can range from didactic to 
interactive engagement and may coincide with developing 
mentoring models between specialist PPC teams and 
nephrology teams. Nephrology teams need to develop 
sustainable models for providing PPC in the RSC pathway.
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table 4.  symptom management in children.
symptoms Causes drug and doses Comments
nausea and vomiting Uraemia, metabolic acidosis, 
gastric paresis, constipation
Odansetron 2–4 mg, 8-h.
Lactulose/sorbitol prn; Movicol half to  
1 sachet
This may have long-term issues and a 
dietitian’s input is useful.
Poor appetite Uraemia, pill burden, behavioural Allow child to eat what he/she enjoys 
and avoid meal battles
NG tube, gastrostomy, overnight feeds, 
cyproheptadine (Ciplactin), 4 mg daily 
(this is an antihistamine so may cause 
drowsiness)
Include family input and do not force 
food that is not enjoyed.
Pain Depending on region and cause Fentanyl 1–4 µg/kg/h IVI infusion.
Paracetamol 10 mg/kg, 6-h.
Gabapentin 2 mg/kg and titrate up
Morphine is cleared slowly and may 
accumulate. Valeron drops if available. May 
need to stagger different drug dosing.
tetany and bone pain Electrolyte abnormalities,  
e.g. Ca and Mg
Calcium gluconate 0.5 ml/kg slow IVI.
Magnesium chloride 0.4 ml/kg IVI.
One-Alpha (1α-hydroxyvitamin D3) 0.25-
1.0 µg/dose oral.
Ideally, need cardiac monitor or infuse 
over 1 hour.
Attempt to give oral calcium
(Calcium Sandoz), half to 1 effervescent 
tablet per dose.
Magnesium [magnesium chloride oral 
suspension (440 mg = 5 mL), 50 mg/kg/
day in divided doses].
seizures PRES (due to hypertension) or 
electrolyte abnormalities
Treat hypertension or electrolytes.
Phenobarbitone 10–20 mg/dose to max 
of 200 mg per dose/Diazepam 0.1–0.2 
mg/kg or IVI titrated slowly per rectum.
Buccal midazolam 0.1–0.2 mg/kg.
sleep disturbances Poor sleep–wake cycle, anxiety Melatonin 3–5 mg/dose.
Clonidine 1–2 µg/kg, 8-h and increase to 
5 µg/kg.
Aromatherapy and music therapy also 
useful.
anxiety and sadness Play therapy
Counsellor
Antidepressants (citalopram 10 mg/kg)
Ideally, psychiatric services should be 
involved.
Abbreviations: IVI, intravenous infusion; NG, nasogastric.
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Where consultation may be required 
with specialty palliative care during renal 
supportive care
•	 Management	of	refractory	pain	or	other	symptoms
•	 Management	 of	 more	 complex	 depression,	 anxiety,	
grief, and existential distress 
•	 Assistance	 with	 conflict	 resolution	 regarding	 goals	 or	
methods of treatment within families or between staff
•	 Assistance	in	addressing	cases	of	near-futility	measures
•	 Support	of	staff	who	are	caring	for	these	children.
Specific paediatric requirements for symptom 
management (table 4)
•	 In	 the	 setting	 of	 paediatrics,	 many	 drugs	 may	 only	 be	
available on Section 21 application. In cases where 
important drugs are not available, advocacy may be 
required to gain access to these agents.
•	 Devices	 for	 ease	 of	 drug	 administration	 need	 to	 be	
considered including nasogastric tubes or percutaneous 
endoscopic gastrostomies (PEGs) inserted for chronic 
use.
•	 May	 need	 intravenous	 access	 for	 specific	 symptoms	 
such as tetany.
RSc PRIMARY PALLIAtIVE cARE 






•	 Resuscitation	 status	 discussion	 and	 precise	 docu-
mentation of what can and cannot be offered (for 
example, high-flow oxygen but not bag mask ventilation 
and intubation).
Palliative care structures in paediatric nephrology are often 
insufficient. Barriers to establishing a palliative care approach 







Evolving RSC teams should prioritise training in complex 
communication, strengthening interdisciplinary support 
systems and further palliative care education [66].
cONcLUSIONS
Proposed research agenda (adults and 
paediatrics)
•	 Determine	 the	actual	number	of	patients	who	 require	
palliative and supportive care due to ESKD. This should 
be accompanied by a needs assessment of the ESKD 
patient and their families so as to develop a strategic and 
comprehensive approach to address the unique needs 
of our country within our available resources.
•	 Study	the	relevance	of	 internationally recognized com-
munication tools in our South African context.
•	 Develop	prognostic	measures	for	our	setting	given	our	
unique cultural and ethnic diversity. Further research, 
especially in resource-limited environments with a high 
burden of disease, should be encouraged.
•	 Determine	 outcomes	 of	 effective	 supportive	 care	 in	
different categories of ESKD patients, whether on dialysis 
or not.
•	 Compile	a	multi-centre	symptom	inventory	(e.g.	 IPOS-
Renal) of dialysis patients in both the public and private 
sectors.
•	 Aim	 to	 understanding	 the	 special	 needs	 of	 paediatrics	
within these frameworks.
Recommendations
•	 Upskill	 healthcare	 workers	 in	 essential	 communication	
skills.
•	 Establish	 the	 role	 of	 medical	 insurance	 societies	 in	
palliative and supportive care in ESKD.
•	 Highlight	the	hidden	costs	of	dialysis	that	are	not	often	
included by some medical insurers.
•	 Explore	better	arrangements	for	the	provision	of	hidden	
costs, such as packaged care models.
•	 Acknowledge	 that	 multidisciplinary	 cover	 should	 be	
included in the dialysis costs (for the services of a 
dietician, psychologist, social worker, access, etc.).
•	 Basic	medical	insurance	cover:	
– When to join?
– What is provided?
•	 Motivate	 for	 all	 the	 required	 medication	 at	 primary	
healthcare level.
•	 Extend	the	Essential	Drugs	List.
•	 In	 view	 of	 the	 limited	 access	 to	 RRT,	 we	 advocate	 
that renal supportive care should be supported by 
government.
•	 Fund	renal	supportive	care nurses and their training. 
renal palliative and supportive care in south africa
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ADDENDA
Addendum 1: charlson comorbidity Index.
The Charlson Index was developed in 1987 and is based on 1-year mortality data from internal medicine patients admitted 
to a single New York Hospital. It was initially validated in a cohort of breast cancer patients. The index encompasses 
19 medical conditions weighted 1–6 with total scores ranging from 0–37. In the development phase of the index, mortality 
for each disease was converted to a relative risk of death within 12 months. A weight was then assigned to each condition 
based on the relative risk (RR); for example, RR <1.2 = weight 0; RR ≥1.2 < 1.5 = weight 1; RR ≥1.5 < 2.5 = weight 2; 
RR ≥2.5 < 3.5 = weight 3; and for 2 conditions (metastatic solid tumour and AIDS) = weight 6 (70).
Comorbidity score
Prior myocardial infarction 1
Congestive heart failure 1
Peripheral vascular disease 1
Cerebrovascular disease 1
Dementia 1
Chronic pulmonary disease 1
Rheumatologic disease 1
Peptic ulcer disease 1
Mild liver disease 1
Diabetes 1
Cerebrovascular (hemiplegia) event 2
Moderate-to-severe renal disease 2
Diabetes with chronic complications 2
Cancer without metastases 2
Leukemia 2
Lymphoma 2
Moderate or severe liver disease 3
Metastatic solid tumor 6
Acquired immuno-deficiency syndrome (AIDS) 6
doi:10.1371/journal.pone.0154627.t003
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Addendum 2: Karnofsky Performance Scale.
The Karnofsky Performance Scale allows patients to be classified according to their functional impairment. This can be used 
to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the Karnofsky 
score, the worse the survival for most serious illnesses.
KarnOFsKY PerFOrManCe status  
sCale deFinitiOns rating (%) Criteria
REFERENcES:
Crooks V, Waller S, et al. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric 
outpatients. J Gerontol. 1991; 46:M139-M144.
de Haan R, Aaronson A, et al. Measuring quality of life in stroke. Stroke. 1993; 24:320-327.
Hollen PJ, Gralla RJ, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. 
Cancer. 1994; 73:2087-2098.
O’Toole DM, Golden AM. Evaluating cancer patients for rehabilitation potential. West J Med. 1991; 155:384-387.
Oxford Textbook of Palliative Mediicine, Oxford University Press. 1993; 109.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncology. 
1983; 2:187-193.
Able to carry on normal activity and to work; no special  
cared needed.
100 Normal no complaints; no evidence of disease.
90
Able to carry on normal activity; minor signs or 
symptoms of disease.
80
Normal activity with effort; some signs or symptoms of 
disease.
Unable to work; able to live at home and care for most 
personal needs; varying amount of assistance needed.
70
Cares for self; unable to carry on normal activity or to do 
active work.
60
Requires occasional assistance, but is able to care for 
most of his personal needs.
50
Requires considerable assistance and frequent  
medical care.
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be 
progressing rapidly.
40 Disabled; requires special care and assistance.
30
Severely disabled, hospital admission is indicated although 
death not imminent.
20
Very sick; hospital admission necessary; active supportive 
treatment necessary.
10 Moribund; fatal processes progressing rapidly.
0 Dead
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Addendum 3: IPOS-Renal.
iPOs-renal Patient versiOn
not at all slightly Moderately severely Overwhelmingly
Pain 0 1 2 3 4
Shortness of breath 0 1 2 3 4
Weakness or lack  
of energy 0 1 2 3 4
Nausea (feeling like you 
are going to be sick) 0 1 2 3 4
Vomitting (being sick) 0 1 2 3 4
Poor appetite 0 1 2 3 4
Constipation 0 1 2 3 4
Sore or dry mouth 0 1 2 3 4
Drowsiness 0 1 2 3 4
Poor mobility 0 1 2 3 4
Itching 0 1 2 3 4
Difficulty sleeping 0 1 2 3 4
Restless legs or difficulty 
keeping legs still 0 1 2 3 4
Changes in skin 0 1 2 3 4
Diarrhoea 0 1 2 3 4
Please list any other symptoms not mentioned above, and tick the box to show how they have affected you over 
the past 3 days.
1.
0 1 2 3 4
2.
0 1 2 3 4
3.
0 1 2 3 4
Patient name:
Date (dd/mm/yyyy):
Patient number:             (for staff use)




Q2.  Below is a list of symptoms, which you may or may not have experienced. For each symptom, please tick the box that 
best describes how it has affected you over the past 3 days.
www.pos-pal.org
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Addendum 3: IPOS-Renal cont.
Over tHe Past 3 daYs:
not at all Occasionally sometimes Most of  the time always
Q3.  Have you been feeling anxious or 
worried about your illness or 
treatment?
0 1 2 3 4
Q4.  Have any of your family or friends 
been anxious or worried about you?
0 1 2 3 4
Q5. Have you been feeling depressed? 0 1 2 3 4
always Most of  the time sometimes Occasionally not at all
Q6. Have you felt at peace? 0 1 2 3 4
Q7:  Have you been able to share how 
you are feeling with your family or 
friends as much as you wanted?
0 1 2 3 4
Q8.  Have you had as much information as 
you wanted?

















Q9.  Have any practical problems resulting 
from your illness been addressed? 
(such as financial or personal)
0 1 2 3 4
none at all up to half a day wasted
More than half  
a day wasted
Q10.  How much time do you feel has 
been wasted on appointments 
relating to your healthcare,  
e.g. waiting around for transport  
of repeating tests?
0 2 4
On my own With help from a friend or relative
With help from a 
member of staff
Q11.  How did you complete this 
questionnaire?
if you are worried about any of the issues raised on this questionnaire,  
then please speak to your doctor or nurse.
IPOS-Renal Patient IPOS-Renal-P3-EN 21/05/2015
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Addendum 4: Useful online resources.
SA hypertension guidelines
https://www.hypertension.org.za/guidelines
Kidney Disease: Improving Global Outcomes




Blood pressure and CKd
https://kdigo.org/guidelines/blood-pressure-in-ckd/
Assessment tools





serious illness Conversation guide
https://www.ariadnelabs.org/wp-content/uploads/sites/2/2015/08/Serious-Illness-Conversation-Guide-5.22.15.pdf
care planning tools
Hospice Palliative Care association of south africa (HPCa) advance Health Care Planning
https://hpca.co.za/wp-content/uploads/2019/06/HPCA-Advanced-HealthCare-Planning-Document-2018.pdf
Find a palliative care provider
https://palprac.org/palliative-care/find-a-provider
become an associate member of PalPrac
https://palprac.org/palprac/join-us/
